Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada.

In April this year, Sandoz was granted a Notice of Compliance from Health Canada for Erelzi to treat moderately to severely active rheumatoid arthritis (RA) in adults with or without methotrexate, and reduce signs and symptoms of active ankylosing spondylitis (AS).

The treatment is currently the only biosimilar approved for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged between four and 17 who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

Sandoz Canada president and general manager Michel Robidoux said: “Biologics have revolutionised the treatment and prevention of many disabling and life-threatening diseases.

"Launching Erelzi is another concrete example of how Sandoz is making access happen by offering high-quality medicines at a more affordable price, which will deliver important savings to the healthcare system."

“However, they are contributing to the rising costs of healthcare, and this may restrict access to these important medicines.

“Unfortunately, as it stands today, not all Canadians living with the debilitating disease have the same access to biologics. There is a growing population that has a relatively high prevalence of immunological diseases, such as rheumatoid arthritis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Launching Erelzi is another concrete example of how Sandoz is making access happen by offering high-quality medicines at a more affordable price, which will deliver important savings to the healthcare system.”

Erelzi is available in a pre-filled syringe (PFS) and a pre-filled pen (PFP), SensoReady, which has an ergonomic device for patients with limited dexterity.

SensoReady is currently available in 25mg and 50mg PFS, and is the only etanercept available in a 25mg PFS.